Board Meeting Details

The Board of Directors meeting was held on Wednesday, 28 October 2026, commencing at 03:10 p.m. and concluding at 04:25 p.m.

Key Financial Results - Consolidated (₹ in Lakhs)

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue from operations: ₹19,669.91 (vs ₹16,266.62) - 20.9% increase
  • Other income: ₹598.43 (vs ₹1,016.55) - 41.1% decrease
  • Total Income: ₹20,268.34 (vs ₹17,283.17) - 17.3% increase
  • Profit before tax: ₹7,103.25 (vs ₹5,953.37) - 19.3% increase
  • Tax expense: ₹1,922.14 (vs ₹1,275.55) - 50.7% increase
  • Profit for the period: ₹5,181.11 (vs ₹4,677.82) - 10.8% increase
  • Total Comprehensive Income: ₹5,158.88 (vs ₹4,419.48) - 16.7% increase
  • Basic EPS: ₹4.59 (vs ₹4.20)

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue from operations: ₹35,496.96 (vs ₹28,758.37) - 23.4% increase
  • Other income: ₹1,142.97 (vs ₹1,532.40) - 25.4% decrease
  • Total Income: ₹36,639.93 (vs ₹30,290.77) - 21.0% increase
  • Profit before tax: ₹12,532.51 (vs ₹10,360.57) - 21.0% increase
  • Tax expense: ₹3,292.71 (vs ₹2,555.83) - 28.8% increase
  • Profit for the period: ₹9,239.80 (vs ₹7,804.74) - 18.4% increase
  • Total Comprehensive Income: ₹9,212.36 (vs ₹7,262.96) - 26.8% increase
  • Basic EPS: ₹8.18 (vs ₹7.05)

Consolidated Balance Sheet (as of 30 September 2026 vs 31 March 2026):

  • Total Assets: ₹1,32,862.70 (vs ₹1,17,487.65) - 13.1% increase
  • Property, plant and equipment: ₹40,056.54 (vs ₹22,399.90) - 78.8% increase
  • Capital work-in-progress: ₹5,378.15 (vs ₹17,843.25) - 69.9% decrease
  • Inventories: ₹27,494.99 (vs ₹21,604.65) - 27.3% increase
  • Trade receivables: ₹24,609.21 (vs ₹22,754.43) - 8.2% increase
  • Cash and cash equivalents: ₹5,379.00 (vs ₹2,673.92) - 101.1% increase
  • Total Equity: ₹97,282.93 (vs ₹89,809.18) - 8.3% increase
  • Total Liabilities: ₹35,579.77 (vs ₹27,678.47) - 28.5% increase
  • Borrowings (non-current + current): ₹18,767.46 (vs ₹14,828.78) - 26.6% increase

Consolidated Cash Flow (H1 FY27):

  • Net cash from operating activities: ₹4,350.31
  • Net cash used in investing activities: ₹(3,285.56)
  • Net cash from financing activities: ₹1,612.38
  • Net increase in cash: ₹2,677.13

Key Financial Results - Standalone (₹ in Lakhs)

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue from operations: ₹13,741.31 (vs ₹8,788.16) - 56.4% increase
  • Other income: ₹1,050.93 (vs ₹1,282.74) - 18.1% decrease
  • Total Income: ₹14,792.24 (vs ₹10,070.90) - 46.9% increase
  • Profit before tax: ₹5,677.27 (vs ₹3,990.32) - 42.3% increase
  • Tax expense: ₹1,443.34 (vs ₹1,016.18) - 42.0% increase
  • Profit for the period: ₹4,233.93 (vs ₹2,974.14) - 42.4% increase
  • Basic EPS: ₹3.74 (vs ₹2.67)

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue from operations: ₹24,309.64 (vs ₹16,805.58) - 44.6% increase
  • Other income: ₹2,030.96 (vs ₹1,944.70) - 4.4% increase
  • Total Income: ₹26,340.60 (vs ₹18,750.28) - 40.5% increase
  • Profit before tax: ₹10,218.02 (vs ₹7,372.97) - 38.6% increase
  • Tax expense: ₹2,601.24 (vs ₹1,878.34) - 38.5% increase
  • Profit for the period: ₹7,616.78 (vs ₹5,494.63) - 38.6% increase
  • Basic EPS: ₹6.74 (vs ₹4.97)

Segment Information - Consolidated

The Group operates in two segments:

1. Pharmaceutical, food and nutrition

2. Speciality ingredients

Q2 FY27 Segment Revenue:

  • Pharmaceutical, food and nutrition: ₹14,249.96 (external)
  • Speciality ingredients: ₹5,419.95 (external)
  • Inter-segment revenue: ₹315.41

Q2 FY27 Segment Results:

  • Pharmaceutical, food and nutrition: ₹5,512.34 (after depreciation)
  • Speciality ingredients: ₹1,273.79 (after depreciation)

IPO Proceeds Utilization

The company's equity shares were listed on NSE and BSE on 28 November 2025. Net IPO proceeds received: ₹8,833.59 lakhs

Utilization as of 30 September 2026:

  • Capital expenditure for Nandesari Facility I: ₹2,000.33 lakhs utilized of ₹7,581.40 lakhs allocated (₹5,581.07 lakhs unutilized)
  • General corporate purposes: ₹1,252.19 lakhs fully utilized
  • Total utilized: ₹3,252.52 lakhs
  • Unutilized proceeds of ₹5,581.07 lakhs are kept as term deposits in bank

Acquisition Details

The Group, through its subsidiary, acquired 85% equity interest in Nutrition Supplier & Services (Ireland) Limited (NSS) on 22 May 2025 for ₹12,857.63 lakhs. NSS became a step-down subsidiary. Final purchase price allocation was completed in Q1 FY27.

Subsidiary Information

The consolidated results include the following entities:

1. Sudeep Pharma Limited (Parent)

2. Sudeep Nutrition Private Limited (Wholly owned subsidiary)

3. Sudeep Pharma USA Inc. (Wholly owned subsidiary)

4. Sudeep Pharma B.V (Wholly owned subsidiary)

5. Sudeep Advanced Materials Private Limited (Wholly owned subsidiary)

6. Nutrition Supplies & Services (Ireland) Limited (Step down subsidiary)

One subsidiary with total assets of ₹10,637.30 lakhs and revenue of ₹1,229.77 lakhs for Q2 FY27 was not reviewed but was considered not material to the Group.

Dividend Declaration

The company paid a dividend of ₹1,694.04 lakhs during H1 FY27.

Auditor Review

The financial results were reviewed by B S R and Co, Chartered Accountants (Firm Registration No.: 128510W), who issued an unmodified limited review report.

Additional Information

The unaudited financial results are available on the Stock Exchange websites (bseindia.com and nseindia.com) and the Company's website (www.sudeepgroup.com).